Media Coverage

Quest Diagnostics reported today that its second quarter revenues grew a little less than 2 percent year over year.[CR-LF][CR-LF]For the three months ended June 30, total revenues reached $1.95 billion, up from $1.92 billion a year ago, and beating the consensus Wall Street estimate of $1.94 billion.[CR-LF][CR-LF]Quest Diagnostic Information Services revenues also grew about 2 percent to $1.87 billion from $1.84 billion. On a conference call, Quest CFO Mark Guinan said that the increase was driven by strong volume growth and acquisitions, but partially offset by higher reimbursement pressures and patient concessions.

Quest Diagnostics compiles data on more than 10 million drug tests a year. Only a small number of companies have struck marijuana from the list of drugs they screen for, and nationally, roughly 99 percent of all general work force drug tests include marijuana.[CR-LF][CR-LF]“For the most part it hasn’t had a large effect in those recreational-use states and no measurable effect in the medical marijuana states,” said Barry Sample, Quest’s senior director for science and technology.

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the expansion of the Global Diagnostics Network (GDN), a strategic working group of major diagnostic laboratories collaborating to generate enhanced diagnostics insights to improve the delivery of global healthcare. Regional companies LSI Medience, and Strand Life Sciences join Quest and the charter members -- Al Borg Medical Laboratories, Dasa, GC Labs, Healius, KingMed Diagnostics, SYNLAB – as GDN members.

Quest Diagnostics said today it has entered an agreement to provide Catholic Health Services of Long Island with laboratory management services and reference testing.[CR-LF][CR-LF]Under the agreement, Quest will provide CHS with lab testing as well as management of lab equipment, supplies, and procurement processes. The agreement covers six CHS hospitals, a core lab, a cancer center, and an infusion center.

Digital health firm Sharecare said today that it is collaborating with Quest Diagnostics on tools for digital health management.[CR-LF][CR-LF]As part of the collaboration, Quest has made a strategic investment of an undisclosed amount in Sharecare, which named Quest its preferred laboratory partner. The development of disease management programs and other services will also be explored, they said.

HHS recently announced the creation of the Quality Summit, which will bring together federal and private healthcare stakeholders to evaluate and streamline federal value-based care programs.[CR-LF][CR-LF]The summit is in response to the Trump Administration’s recent executive order calling for greater healthcare price and quality transparency. Physicians in a 2018 report from Quest Diagnostics also called for less complex quality measurement.

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today launched a new Lyme Disease test offering that individuals can purchase through Quest’s consumer-initiated testing service, QuestDirect.[CR-LF][CR-LF]The blood test screens for immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies produced by the body to fight infection to the bacterium that causes Lyme disease. Through this service, individuals who suspect they have been bitten by a tick carrying Lyme disease can purchase laboratory tests to aid in the identification of Lyme Disease. Individuals 18 years of age or older may access the test service at any of Quest’s 2,250 patient service centers across the United States without first needing to consult a physician. The service is available in 45 states starting today.

In a fascinating LinkedIn post titled, “Who’s Responsible For Healthcare's Biggest Problems? 'Not Me.',” ​former Permanente Medical Group Chief Executive Officer and Exxecutive Director Robert Pearl, MD, observes that there is a lot of finger pointing at the “culprits” to blame for America’s failures to improve clinical outcomes and contain spending. [CR-LF]A recent Quest Diagnostics study presented at the recent ADA 79th Scientific Sessions found that individuals at risk of developing type 2 diabetes who take part in an employer-sponsored wellness program with digital interventions can reduce their risk of developing the chronic disease for up to 8 years. Sixty-two percent of participants lost weight after the DPP, with 31% losing 5% or more of body weight, and levels for all biometric markers in the risk model—including for glycated hemoglobin, high-density lipoproteins (HDL, or "good" cholesterol), fasting glucose, and triglycerides—improved across all study cohorts.

United Health Group announced its plans to invest around $8 million over the next five years to launch a data science initiative with the Atlanta University Center Consortium, a group of historically black colleges and universities (HBCUs), per Forbes. But VBC implementation has been a big headache for providers — and it's slowing adoption.Nearly 80% of US providers say the shift to value-based care reimbursement models hasn't been successful, according to a 2018 Medical Group Management Association survey of 426 individuals from group health practices. Because VBC relies on accurate data collection and reporting to calculate payment, the clerical burden on doctors has significantly increased. And close to 60% of payers think physicians lack the proper tools to find success under a VBC model, according to a 2018 Quest Diagnostics survey. This friction with providers is putting a major drag on VBC adoption: We reported last week that only 25% of healthcare organizations' revenue comes from VBC, per estimates from a 2018 Optum-sponsored survey.

Since the dawn of time, there have been women who get pregnant without a second thought—and in some cases without even trying—and there have been women who have had to endure years of struggling to conceive. Somewhere in between are the women who talk about kids “someday” with no indication of whether or not someday will ever actually come. Beyond that there are women who just don’t know what the future holds for them and for a lot of us, this is a source of existential anxiety.Modern Fertility is a hormone test you can order to your home or take to your local Quest Diagnostics so that you have a clearer picture of your reproductive future.